Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Jun Ma, Zhibin Cheng et al.|New England Journal of Medicine|2019Cited by 934
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu‐Pei Chen, Jun Ma, Xu Liu et al.|The Lancet|2021Cited by 234
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Ling‐Long Tang, Lei Chen et al.|Journal of Clinical Oncology|2022Cited by 147
Enhanced expression of SETDB1 possesses prognostic value and promotes cell proliferation, migration and invasion in nasopharyngeal carcinomaJing Huang, Zhonghua Yu|Oncology Reports|2018Cited by 17
Dysregulated gene expression of SUMO machinery components induces the resistance to anti-PD-1 immunotherapy in lung cancer by upregulating the death of peripheral blood lymphocytesYing Wang, Jing Huang|Frontiers in Immunology|2024Cited by 4